Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +36.87%
#3 Nockchain Nockchain +22.61%
#4 Fabric Protocol Fabric Protocol +19.38%
#5 Bedrock Bedrock +16.78%
#6 Cysic Cysic +15.00%
#7 Perle Perle +12.14%
#8 Tutorial Tutorial +6.24%
#9 Anvil Anvil +6.20%
#10 Arowana Arowana +6.03%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Vanta Bioscience Limited Vanta Bioscience Limited

Vanta Bioscience Limited

VANTABIO
Rank in Stocks #37651
Vanta Bioscience Limited functions as an all-encompassing preclinical contract... Vanta Bioscience Limited functions as an all-encompassing preclinical contract research organization (CRO). The firm extends a wide array of specialized offerings, including Discovery Toxicology, comprehensive assessments for Agro-Chemicals and overall Chemical Safety, Biocompatibility Studies, Diet Formulation, and Batch Release Testing. This company commenced operations on April 29, 2016, and its main office is situated in Hyderabad, India.
Share Price
$0.21674463
Last synced: 2026-08-13
Market Cap
$1.54M
Change (1 day)
-4.98%
Change (1 year)
-25.87%
Country
IN
Trade Vanta Bioscience Limited (VANTABIO)

Category

Healthcare
P/E ratio for Vanta Bioscience Limited (VANTABIO)
P/E ratio as of 2026 TTM: 0
According to Vanta Bioscience Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Vanta Bioscience Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.